Gangguan Afektif Bipolar

01Pathophysiology

Bipolar Affective Disorder is fundamentally a disorder of mood regulation circuitry. The prevailing neurobiological model centers on dysregulation of monoamine neurotransmitters, particularly dopamine, serotonin, and norepinephrine, within prefrontal-limbic networks.

During a manic episode, there is a relative excess of dopaminergic and noradrenergic activity. This explains the characteristic increased energy, grandiosity, decreased need for sleep, and psychomotor agitation. The prefrontal cortex, which normally exerts "top-down" inhibitory control over the limbic system (especially the amygdala), becomes functionally underactive. This loss of inhibition is why manic patients display poor judgment, impulsivity, and disinhibited behavior despite appearing highly energetic and "productive."

During a depressive episode, the balance shifts toward relative monoamine deficiency, particularly serotonin and norepinephrine. This correlates with decreased energy, psychomotor retardation, anhedonia, and vegetative symptoms (sleep disturbance, appetite changes). The depressive phase tends to last longer than the manic phase. Per PPDGJ-III, manic episodes typically last 2 weeks to 4-5 months, while depressive episodes average around 6 months and rarely exceed 1 year, except in elderly patients.

A critical concept from PPDGJ-III is the principle of complete inter-episode recovery. This distinguishes bipolar disorder from conditions like schizoaffective disorder or schizophrenia, where functional decline between episodes is expected. On an exam, a vignette describing a patient who returns to baseline functioning between mood episodes strongly points toward bipolar disorder.

The kindling hypothesis is also testable: with each successive untreated episode, the threshold for triggering the next episode decreases, and episodes may eventually occur spontaneously without psychosocial stressors. This underscores why long-term maintenance therapy is essential.

02Classification and Clinical Manifestation

PPDGJ-III classifies Bipolar Affective Disorder based on the nature of the current episode. A diagnosis requires at least two episodes of mood disturbance, with at least one being a manic, hypomanic, or mixed episode.

The distinction between hypomania and mania is critical. Hypomania involves elevated mood and increased activity that is noticeable to others but does not cause severe social or occupational dysfunction and has no psychotic features. Mania, by contrast, is severe enough to disrupt functioning significantly, may require hospitalization, and can include psychotic symptoms.

The mixed episode subtype is a frequent exam target. Per PPDGJ-III, the patient must show symptoms of both mania/hypomania and depression that are equally prominent and rapidly alternating, with the current mixed episode lasting at least 2 weeks. This is different from a patient who simply has irritable mania.

Note that PPDGJ-III explicitly states that Bipolar Affective Disorder includes "gangguan manik-depresif" (manic-depressive disorder or manic-depressive psychosis), but it excludes single manic episodes (which are classified separately) and cyclothymia.

03Diagnostic Workup

Bipolar Affective Disorder is a clinical diagnosis. There is no blood test, imaging study, or biomarker that confirms it. The diagnosis rests entirely on meeting PPDGJ-III criteria through careful history-taking.

The best initial step in a vignette presenting with mood symptoms is always a thorough psychiatric history with collateral information. You must establish two things: (1) the current episode meets criteria for a recognized mood episode (manic, hypomanic, depressive, or mixed), and (2) the patient has had at least one prior affective episode of any type.

The most important diagnostic pitfall is missing the history of mania or hypomania. A patient who presents with depression and has a hidden history of hypomanic episodes will be misdiagnosed as having unipolar depression. This is why collateral history and direct questioning about prior elevated mood, decreased need for sleep, increased goal-directed activity, and spending sprees are essential.

Laboratory tests are ordered to rule out organic mimics, not to confirm bipolar disorder. Thyroid function is the highest-yield lab: hyperthyroidism causes anxiety, irritability, weight loss, and hyperactivity that closely resembles mania. Urine drug screen is similarly important because cocaine and amphetamine intoxication can produce a clinical picture indistinguishable from acute mania.

Per PPDGJ-III, the diagnostic framework also requires distinguishing bipolar disorder from schizoaffective disorder by confirming that psychotic symptoms (when present) are mood-congruent and occur only during mood episodes, not independently.

04Management and Treatment

Acute mania: The first priority is to assess severity and ensure patient safety. If the patient is severely agitated or poses a danger to self or others, short-term benzodiazepines (lorazepam) can be given for immediate behavioral control while initiating a mood stabilizer. Lithium is the classic first-line agent for acute mania. It takes 5-7 days to reach therapeutic effect, so in clinical practice it is often combined with an atypical antipsychotic for faster symptom control. Valproic acid is preferred over lithium in mixed episodes, rapid cycling, or when lithium is contraindicated (renal impairment, pregnancy concern for Ebstein anomaly at lower risk than previously thought, but still a concern).

Acute bipolar depression: This is the most tested management scenario. The cardinal rule is: never prescribe antidepressant monotherapy (SSRIs, SNRIs, TCAs) to a patient with bipolar disorder. Antidepressant monotherapy carries the risk of triggering a manic switch or inducing rapid cycling. The correct first-line treatment is quetiapine monotherapy or a mood stabilizer (lithium or lamotrigine). If an antidepressant is deemed necessary, it should always be combined with a mood stabilizer.

Maintenance therapy: Bipolar disorder is a lifelong condition requiring indefinite maintenance therapy. Lithium remains the gold standard because it has the strongest evidence for preventing both manic and depressive relapses and is the only psychiatric medication with robust evidence for reducing suicide risk. Lamotrigine is the preferred maintenance agent when depressive relapses predominate. Regular monitoring during lithium therapy includes serum lithium levels (every 3-6 months once stable), renal function (creatinine, BUN), thyroid function (TSH), and calcium levels.

Lithium toxicity is a high-yield exam topic. Early signs include tremor, nausea, diarrhea, and ataxia. Severe toxicity (levels >2.0 mEq/L) can cause seizures, renal failure, and cardiac arrhythmias. Risk factors for toxicity include dehydration, NSAIDs, ACE inhibitors, and thiazide diuretics (all reduce lithium clearance). Management of severe toxicity is hemodialysis.

Contraindications & Precautions

• Lithium: avoid in severe renal impairment; use with caution in pregnancy (small risk of Ebstein anomaly); avoid concurrent NSAIDs and thiazides

• Valproate: contraindicated in pregnancy (neural tube defects, risk ~1-2%); monitor liver function and platelets; associated with weight gain and polycystic ovarian syndrome

• Lamotrigine: requires very slow dose titration; risk of Stevens-Johnson syndrome is highest with rapid titration or concurrent valproate (which doubles lamotrigine levels)

• Carbamazepine: an alternative mood stabilizer; induces CYP450 enzymes (many drug interactions); risk of agranulocytosis and aplastic anemia; also teratogenic

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get bipolar disorder questions wrong is by failing to identify a depressive presentation as bipolar rather than unipolar depression. The vignette will describe a patient in a depressive episode and bury the clue to prior mania in one or two sentences: "The patient's spouse mentions a period last year when she barely slept, spent excessively, and started three new business ventures." Students who skip over this detail will select unipolar depression and, worse, will choose SSRI monotherapy as the treatment, which is the wrong answer in two directions.

The second major trap involves management sequencing. When a vignette describes acute mania, students sometimes jump to long-term maintenance therapy (lamotrigine, for example) rather than selecting the acute treatment (lithium or valproate plus an antipsychotic for severe presentations). Conversely, when asked about preventing depressive relapses, students may select lithium or valproate when lamotrigine is the better choice for that indication.

The third common error is confusing bipolar mixed episodes with agitated depression or borderline personality disorder. PPDGJ-III defines the mixed episode as one where symptoms of mania/hypomania and depression are equally prominent and alternate rapidly, lasting at least 2 weeks. The key discriminator is sustained duration and the presence of true manic symptoms (grandiosity, decreased need for sleep), not just irritability.

Finally, remember that PPDGJ-III emphasizes complete inter-episode recovery as a hallmark. If the vignette describes a patient with residual psychotic symptoms or functional decline between mood episodes, this should push your thinking toward schizoaffective disorder, not bipolar disorder.

The core competency being tested is the ability to recognize bipolar disorder across its different presentations (manic, depressive, mixed, remission), correctly sequence the diagnostic workup (clinical history first, labs to exclude organic causes), and apply the right treatment for the right phase while avoiding the critical error of antidepressant monotherapy.